1st Biosimilars Act Ruling May Limit Patent Challenges

14-11-2013 Law360Comments (0)

AmgenBiosimilars

The ability of biosimilars makers to make early challenges to biologic drug patents may be curtailed by a Tuesday ruling throwing out Sandoz Inc.'s suit to invalidate patents for Amgen Inc.'s biologic ...

Read more on Law360

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top